/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

F

Fanny Piette

International Drug Development Institute (Belgium)(BE)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

58

Papers

5.0K

Citations

19

h-index

24

i10-index

Fanny Piette is an academic researcher from International Drug Development Institute (Belgium). The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Colorectal Cancer Treatments and Studies & HER2/EGFR in Cancer Research. The author has an h-index of 19, co-authored 50 publications.

Research Topics

Lung Cancer Treatments and Mutations Colorectal Cancer Treatments and Studies HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Gastric Cancer Management and Outcomes

Papers by this author

works

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

2013 · Journal of Clinical Oncology · 1,618 citations

https://doi.org/10.1200/jco.2011.41.0902

Sherene Loi Nicolas Sirtaine Fanny Piette Roberto Salgado

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data

2011 · The Lancet Oncology · 191 citations

https://doi.org/10.1016/s1470-2045(11)70231-5

Angelo Di Leo Christine Desmedt John M.S. Bartlett Fanny Piette

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

2019 · Journal of Clinical Oncology · 79 citations

https://doi.org/10.1200/jco.19.00858

Jame Abraham A.J. Montero Rachel C. Jankowitz Mohamad A. Salkeni

Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types

2017 · BMJ Open · 48 citations

https://doi.org/10.1136/bmjopen-2017-017075

Caroline Lonez Bikash Verma Alain Hendlisz Philippe Aftimos

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer

2019 · Breast Cancer Research · 44 citations

https://doi.org/10.1186/s13058-019-1196-y

Samuel A. Jacobs André Robidoux Jame Abraham José Manuel Pérez-García

Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISH

2009 · Diagnostic Molecular Pathology · 39 citations

https://doi.org/10.1097/pdm.0b013e31818ebc69

Christine Desmedt Jeff Sperinde Fanny Piette Weidong Huang

Research topics

topics

Lung Cancer Treatments and Mutations

Colorectal Cancer Treatments and Studies

HER2/EGFR in Cancer Research

Breast Cancer Treatment Studies

Gastric Cancer Management and Outcomes

Chat about Author

Papers

Chat

Click to start Chat